Search Results - "Rosner, Gary"

A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real‐world evidence by Wang, Chenguang, Rosner, Gary L.

“…With the wide availability of various real‐world data (RWD), there is an increasing interest in synthesizing information from both randomized clinical trials…”
Get full text

A Bayesian model with application for adaptive platform trials having temporal changes by Wang, Chenguang, Lin, Min, Rosner, Gary L., Soon, Guoxing

“…Temporal changes exist in clinical trials. Over time, shifts in patients' characteristics, trial conduct, and other features of a clinical trial may occur. In…”
Get full text

Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models by Henderson, Nicholas C, Louis, Thomas A, Rosner, Gary L, Varadhan, Ravi

“…Individuals often respond differently to identical treatments, and characterizing such variability in treatment response is an important aim in the practice of…”
Get full text

A Prospective Study of Hippocampal-Sparing Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) by Redmond, Kristin J., M.D., M.P.H, Hales, Russell K., M.D, Anderson-Keightly, Heather, B.S, Zhou, Xian C., M.S, Kummerlowe, Megan, B.S, Sair, Haris, M.D, Duhon, Mario, B.S, Kleinberg, Lawrence, M.D, Rosner, Gary L., Sc.D, Vannorsdall, Tracy, Ph.D

“…Abstract Objectives Neurocognitive toxicity may be related to hippocampal dose. This prospective study evaluated cognitive function and intra-cranial failure…”
Get full text

Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline by GRIGGS, Jennifer J, MANGU, Pamela B, SHAYNE, Michelle, SPARREBOOM, Alex, SUCHESTON, Lara E, LYMAN, Gary H, ANDERSON, Holly, BALABAN, Edward P, DIGNAM, James J, HRYNIUK, William M, MORRISON, Vicki A, MAY PINI, T, RUNOWICZ, Carolyn D, ROSNER, Gary L

“…To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. The American Society of Clinical Oncology…”
Get full text

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response by Lee, Shawn H. R., Yang, Wenjian, Gocho, Yoshihiro, John, August, Rowland, Lauren, Smart, Brandon, Williams, Hannah, Maxwell, Dylan, Hunt, Jeremy, Yang, Wentao, Crews, Kristine R., Roberts, Kathryn G., Jeha, Sima, Cheng, Cheng, Karol, Seth E., Relling, Mary V., Rosner, Gary L., Inaba, Hiroto, Mullighan, Charles G., Pui, Ching-Hon, Evans, William E., Yang, Jun J.

“…Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical features, leukemia genomics and minimal residual…”
Get full text

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update by Griggs, Jennifer J, Bohlke, Kari, Balaban, Edward P, Dignam, James J, Hall, Evan T, Harvey, R Donald, Hecht, Diane P, Klute, Kelsey A, Morrison, Vicki A, Pini, T May, Rosner, Gary L, Runowicz, Carolyn D, Shayne, Michelle, Sparreboom, Alex, Turner, Sophia, Zarwan, Corrine, Lyman, Gary H

“…To provide recommendations for appropriate dosing of systemic antineoplastic agents in obese adults with cancer. A systematic review of the literature…”
Get full text

Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods by Hong, Hwanhee, Wang, Chenguang, Rosner, Gary L

“…Background/aims: Regulatory approval of a drug or device involves an assessment of not only the benefits but also the risks of adverse events associated with…”
Get full text

Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments by Tannock, Ian F, Ratain, Mark J, Goldstein, Daniel A, Lichter, Allen S, Rosner, Gary L, Saltz, Leonard B

Get full text

DPpackage : Bayesian Semi- and Nonparametric Modeling in R by Jara, Alejandro, Hanson, Timothy, Quintana, Fernando, Müller, Peter, Rosner, Gary

“…Data analysis sometimes requires the relaxation of parametric assumptions in order to gain modeling flexibility and robustness against mis-specification of the…”
Get full text

Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies by Siu, Lillian L, Ivy, S Percy, Dixon, Erica L, Gravell, Amy E, Reeves, Steven A, Rosner, Gary L

“…Immunotherapy adds an exciting new dimension to the treatment of cancer, joining other approaches as a key pillar in the oncotherapeutics armamentarium…”
Get full text

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics by INNOCENTI, Federico, KROETZ, Deanna L, SCHUETZ, Erin, DOLAN, M. Eileen, RAMIREZ, Jacqueline, RELLING, Mary, PEIXIAN CHEN, DAS, Soma, ROSNER, Gary L, RATAIN, Mark J

“…We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in irinotecan (CPT-11) pharmacokinetics and…”
Get full text

A Product Partition Model With Regression on Covariates by Müller, Peter, Quintana, Fernando, Rosner, Gary L.

“…We propose a probability model for random partitions in the presence of covariates. In other words, we develop a model-based clustering algorithm that exploits…”
Get full text

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide by McCurdy, Shannon R., Kanakry, Jennifer A., Showel, Margaret M., Tsai, Hua-Ling, Bolaños-Meade, Javier, Rosner, Gary L., Kanakry, Christopher G., Perica, Karlo, Symons, Heather J., Brodsky, Robert A., Gladstone, Douglas E., Huff, Carol Ann, Pratz, Keith W., Prince, Gabrielle T., Dezern, Amy E., Gojo, Ivana, Matsui, William H., Borrello, Ivan, McDevitt, Michael A., Swinnen, Lode J., Smith, B. Douglas, Levis, Mark J., Ambinder, Richard F., Luznik, Leo, Jones, Richard J., Fuchs, Ephraim J., Kasamon, Yvette L.

“…Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide (PTCy) is being increasingly used because…”
Get full text

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer by Marrone, Kristen A., Zhou, Xian, Forde, Patrick M., Purtell, Michael, Brahmer, Julie R., Hann, Christine L., Kelly, Ronan J., Coleman, Barbara, Gabrielson, Edward, Rosner, Gary L., Ettinger, David S.

“…Background In the absence of a targeted oncogenic driver mutation or high programmed death‐ligand 1 expression, systemic therapy with platinum‐based doublet…”
Get full text

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition by Ramsey, Laura B, Bruun, Gitte H, Yang, Wenjian, Treviño, Lisa R, Vattathil, Selina, Scheet, Paul, Cheng, Cheng, Rosner, Gary L, Giacomini, Kathleen M, Fan, Yiping, Sparreboom, Alex, Mikkelsen, Torben S, Corydon, Thomas J, Pui, Ching-Hon, Evans, William E, Relling, Mary V

“…Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of…”
Get full text

Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer by Litvak, Anya, Batukbhai, Bhavina, Russell, Stuart D., Tsai, Hua‐Ling, Rosner, Gary L., Jeter, Stacie C., Armstrong, Deborah, Emens, Leisha A., Fetting, John, Wolff, Antonio C., Silhy, Raquel, Stearns, Vered, Connolly, Roisin M.

“…BACKGROUND Human epidermal growth factor receptor 2 (HER2)‐targeted therapies are highly effective at preventing breast cancer recurrence but are associated…”
Get full text

Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma by Noonan, Kimberly A, Huff, Carol A, Davis, Janice, Lemas, M Victor, Fiorino, Susan, Bitzan, Jeffrey, Ferguson, Anna, Emerling, Amy, Luznik, Leo, Matsui, William, Powell, Jonathan, Fuchs, Ephraim, Rosner, Gary L, Epstein, Caroline, Rudraraju, Lakshmi, Ambinder, Richard F, Jones, Richard J, Pardoll, Drew, Borrello, Ivan

“…Successful adoptive T cell therapy (ACT) requires the ability to activate tumor-specific T cells with the ability to traffic to the tumor site and effectively…”
Get more information

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma by RATAIN, Mark J, EISEN, Tim, ROWINSKY, Eric, ABBRUZZESE, James L, CHENGHUA XIA, SIMANTOV, Ronit, SCHWARTZ, Brian, O'DWYER, Peter J, STADLER, Walter M, FLAHERTY, Keith T, KAYE, Stan B, ROSNER, Gary L, GORE, Martin, DESAI, Apurva A, PATNAIK, Amita, XIONG, Henry Q

“…This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and…”
Get full text

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults by Kasamon, Yvette L, Bolaños-Meade, Javier, Prince, Gabrielle T, Tsai, Hua-Ling, McCurdy, Shannon R, Kanakry, Jennifer A, Rosner, Gary L, Brodsky, Robert A, Perica, Karlo, Smith, B Douglas, Gladstone, Douglas E, Swinnen, Lode J, Showel, Margaret M, Matsui, William H, Huff, Carol Ann, Borrello, Ivan, Pratz, Keith W, McDevitt, Michael A, Gojo, Ivana, Dezern, Amy E, Shanbhag, Satish, Levis, Mark J, Luznik, Leo, Ambinder, Richard F, Fuchs, Ephraim J, Jones, Richard J

“…Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study…”
Get full text